로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CKP > BAFF > BAF-H82Q2

Biotinylated Human BAFF / TNFSF13B / CD257 Protein, His,Avitag™ (active trimer) (MALS verified)

인기 제품 추천: SP-11 스트렙타비딘 코팅된 96웰 플레이트  샘플 신청 
STN-N5116 스트렙타비딘 단백질  SMB-B01 스트렙타비딘 마그네틱 비드 
비오틴-스트렙타비딘 시스템의 높은 특이성과 고감도를 이용하여 비오틴화된 단백질을 스트렙타비딘 관련 제품과 결합하여 다양한 실험에서 사용할 수 있습니다. 비비오틴 시스템과 비교하면 검출이 더 빠르고 더 강력하고 더 낮은 비특이적 배경을 가지고 있습니다.
  • 동의어
    TNFSF13B,BAFF,BLYS,CD257,DTL,TALL1,THANK,TNFSF20,ZTNF4,TALL-1
  • 출처
    Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (BAF-H82Q2) is expressed from human 293 cells (HEK293). It contains AA Ala 134 - Leu 285 (Accession # AAH20674.1).
    Predicted N-terminus: His
  • 분자 표징
    Online(Ala 134 - Leu 285) AAH20674.1

    This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 20.2 kDa. The protein migrates as 21-23 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 비오틴화
    비오틴화 of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • 내독소
    Less than 1.0 EU per μg by the LAL method.
  • 순도

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • 레시피

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • 재구성

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 보관

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) SDS-PAGE gel

Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. ) MALS images

The purity of Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) is more than 90% in HP-SEC, and the molecular weight of this protein is around 60-75 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified)Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) ELISA bioactivity

Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 2 μg/mL (100 μL/well) can bind Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) with a linear range of 0.2-4 ng/mL (QC tested).

Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified)Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) ELISA bioactivity

Immobilized Human TACI/TNFRSF13B, Fc Tag (Cat. No. TAI-H5256) at 2 μg/mL (100 μL/well) can bind Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) with a linear range of 0.2-3 ng/mL (Routinely tested).

Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified)Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) ELISA bioactivity

Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Anti-BCMA MAb (Mouse IgG1, the antibody was co developed by SCT and ACRObiosystems) and 0.01 μg/mL (100 μL/well) Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) with a half maximal inhibitory concentration (IC50) of 4.877 μg/mL (Routinely tested).

Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified)Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) ELISA bioactivity

Serial dilutions of Anti-BAFFR Antibody, Human IgG1 were added into Human BAFFR, Llama IgG2b Fc Tag, low endotoxin (Cat. No. BAR-H5258): Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) binding reactions. The half maximal inhibitory concentration (IC50) is 1.1323 μg/mL (Routinely tested).

Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified)Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) ELISA bioactivity

Serial dilutions of Anti-BAFFR Antibody, Human IgG1 were added into Human BAFFR, Fc Tag (Cat. No. BAR-H5257): Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) binding reactions. The half maximal inhibitory concentration (IC50) is 0.7363 μg/mL (Routinely tested).

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) on SA Chip can bind Human TACI/TNFRSF13B, Fc Tag (Cat. No. TAI-H5256) with an affinity constant of 1.35 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Human_FcRn_Heterodimer_Protein_SPR

Immobilized Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) on SA Chip can bind Human BAFFR, Llama IgG2b Fc Tag, low endotoxin (Cat. No. BAR-H5258) with an affinity constant of 35.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human BAFF, His,Avitag (active trimer) (MALS verified) (Cat. No. BAF-H82Q2) on SA Biosensor, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 1.1 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • 백그라운드
    B-cell activating factor (BAFF) is also known as tumor necrosis factor ligand superfamily member 13B , TNFSF13B, BAFF, B Lymphocyte Stimulator (BLyS) , cluster of differentiation 257 (CD257), DTL, TNF- and APOL-related leukocyte expressed ligand (TALL-1), THANK, TNFSF20, ZTNF4, and is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. It is expressed as transmembrane protein on various cell types including monocytes, dendritic cells and bone marrow stromal cells. BAFF is the natural ligand of three unusual tumor necrosis factor receptors named BAFF-R, TACI, and BCMA, all of which have differing binding affinities for it. These receptors are expressed mainly on mature B lymphocytes (TACI is also found on a subset of T-cells and BCMA on plasma cells). TACI binds worst since its affinity is higher for a protein similar to BAFF, called a proliferation-inducing ligand (APRIL). BCMA displays an intermediate binding phenotype and will work with either BAFF or APRIL to varying degrees. Signaling through BAFF-R and BCMA stimulates B lymphocytes to undergo proliferation and to counter apoptosis. All these ligands act as heterotrimers (i.e. three of the same molecule) interacting with heterotrimeric receptors, although BAFF has been known to be active as either a hetero- or homotrimer. BAFF acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. 
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

코멘트 (0)


ETD of in-stock products: 4 business days

가격(KRW) : 472,500

가격(KRW) : 2,052,000

가격(KRW) : 40,500

가격(KRW) : 175,500

가격(KRW) : 283,500

가격(KRW) : 283,500

가격(KRW) : 472,500

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:2 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Approved

데이터 테이블 및 파일

DMF 신청
DMF (Drug Master File)

연락처

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

신제품

의문 과 코맨트

This web search service is supported by Google Inc.

totop